Saturday 17 October 2026
Export DYAI’s income statement to Excel — free account
Dyadic International Inc.
DYAI Healthcare Biotechnology
Dyadic International Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.1 million, down 11.6% from fiscal 2024. In the quarter to June 2026, revenue was flat, EPS was flat, free cash flow fell 1,298.5% and total debt was flat, each against the same quarter a year earlier.
0.41
0.01
−2.38%
Follow DYAI
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
8.63 | 7.84 | 9.92 | 12.18 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(18.04) | (15.20) | (17.32) | (21.98) | |
P/B ratio |
0.00 | 0.00 | 24.88 | 15.62 | |
Price to Tangible BV |
0.00 | 0.00 | 24.88 | 15.62 | |
EV/Sales |
8.72 | 7.45 | 8.78 | 10.61 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(4.48) | (4.96) | (4.76) | (7.66) | |
EV/FCF |
(4.41) | (4.87) | (4.67) | (7.49) | |
Quick Ratio |
1.54 | 2.36 | 2.62 | 2.77 | |
Current Ratio |
1.65 | 2.42 | 2.68 | 2.85 | |
Net Debt/EBITDA |
(0.18) | 0.78 | 2.29 | 2.73 | |
Debt/Assets |
77.12% | 64.45% | 50.53% | 42.95% | |
Debt/Equity |
(2.11) | (12.35) | 4.08 | 1.92 | |
Asset Turnover |
0.52 | 0.48 | 0.31 | 0.30 | |
Operating CF/Net income |
0.86 | 1.00 | 1.13 | 0.94 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Coverage |
(18.78) | (17.42) | (13.55) | (16.87) | |
Research and Development Expense of Revenue |
34.61% | 42.85% | 81.06% | 49.11% | |
Selling, General and Administrative Expense of Revenue |
175.83% | 157.99% | 220.58% | 127.20% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
15.02% | 12.54% | 34.02% | 14.79% | |
Graham Net Nets |
(0.08) | (0.02) | 0.04 | 0.06 | |
Graham Number |
0.58 | 0.24 | 0.00 | 0.00 | |
Earnings Yield |
(25.56%) | (28.05%) | (26.60%) | (20.34%) | |
Free Cash Flow Yield |
(22.91%) | (19.52%) | (18.96%) | (11.64%) | |
Revenue per Share |
0.03 | 0.03 | 0.02 | 0.03 | |
Operating CF per Share |
(0.05) | (0.05) | (0.05) | (0.05) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.05) | (0.05) | (0.05) | (0.05) | |
Cash per Share |
0.13 | 0.18 | 0.26 | 0.30 | |
Shareholders Equity per Share |
(0.07) | (0.01) | 0.04 | 0.08 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(0.07) | (0.01) | 0.04 | 0.08 | |
Free Cash Flow |
(1.82) | (1.96) | (1.77) | (1.85) | |
Working Capital |
2.52 | 4.52 | 6.21 | 7.49 | |
Net Current Asset Value |
(2.52) | (0.52) | 1.18 | 2.48 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
1.03 | 0.63 | 0.69 | 0.67 | |
Average Payables |
0.78 | 0.75 | 0.67 | 0.89 | |
Average Assets |
7.34 | 7.85 | 9.94 | 11.24 | |
Average Common Equity |
(1.46) | 0.26 | 1.85 | 3.01 |
Columns are period end dates